Disease Landscape and Forecast Insights

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common reason for liver transplantation in Europe. The recent market…

Tackling the Market Access Challenges in Brazil, Mexico, and Argentina Increases in seroprevalent cases of hepatitis C virus (HCV), disease awareness, and patient access to HCV treatment…

Nonalcoholic fatty liver disease (NAFLD) is caused by a buildup of fat in the liver. A proportion of NAFLD sufferers will also experience injury to their hepatocytes, which can lead to nonalcoholic…

How Will Healthcare Reform and Payer-Led Cost-Containment Strategies Impact U.S. Prescribing? The market opportunity for hepatitis C virus (HCV) features a large prevalent population, a…

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA…

The Impact of Premium-Priced Market Entrants on MCO-Run Medicare and Medicaid Plans The groundbreaking therapies for the Hepatitis C virus (HCV) promise high cure rates for millions of Americans…

How Will New Market Entrants Fare in the Rapidly Evolving Treatment Landscape? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) infections are a serious public…

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…

Last Updated 29 December 2014 Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of it represents a large untapped market owing to…

Emerging markets present great opportunities but also numerous challenges to multinational pharmaceutical corporations (MNCs). With large and growing populations, robust projected market growth,…

Prevalence of the hepatitis C virus (HCV) in Brazil is estimated to be among the highest in the world; in addition, the country faces the challenge of treating a largely undiagnosed HCV-infected…

Hepatitis C virus (HCV) chronic infection is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The FDA’s approval of Gilead…